Indoco Remedies Limited has formally intimated the stock exchanges regarding the demise of Dr. Anand Nadkarni (DIN: 06881461), Non-Executive Director of the Company, on Friday, 15th May, 2026. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to both the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited.

Regulatory Disclosure Under SEBI Regulation 30

The intimation was filed by Ramanathan Hariharan, Company Secretary & Head Legal of Indoco Remedies, on 15th May, 2026. The filing references SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, under which the requisite details of the cessation have been disclosed as Annexure A.

The following details have been provided as required under the applicable regulatory framework:

Company Pays Tribute

Indoco Remedies expressed profound grief over the sudden and unexpected passing of Dr. Anand Nadkarni. The Company noted that his association as a Non-Executive Director had immensely benefitted the organisation, and described his loss as irreparable. All directors and employees of the Company conveyed deep sympathy, sorrow, and condolences to his family.

Indoco Remedies has secured the EU GMP (Good Manufacturing Practice) Certification from the Malta Medicines Authority, affirming that its facility meets the stringent Good Manufacturing Standards required under European Union regulatory frameworks. This certification is a formal recognition of the company's manufacturing quality and compliance capabilities.

EU GMP Certification: Key Details

The following table summarizes the key details of the certification:

Significance of the Certification

The EU GMP Certification issued by the Malta Medicines Authority is a widely recognized regulatory credential that validates a manufacturing facility's compliance with European Union standards for pharmaceutical production. Obtaining this certification demonstrates that Indoco Remedies' facility adheres to the quality, safety, and operational benchmarks mandated for pharmaceutical manufacturers seeking to operate within or supply to European markets.

This development represents a notable regulatory achievement for Indoco Remedies, reflecting the company's commitment to maintaining internationally recognized manufacturing quality standards.